helmholtzeyeinstituteРоссийский офтальмологический журналRussian Ophthalmological Journal2072-00762587-5760Real time Publishers10.21516/2072-0076-2025-18-1-157-162helmholtzeyeinstitute-1705Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWSФиксированная комбинация латанопроста и тимолола в терапии первичной открытоугольной глаукомыLatanoprost/timolol fixed combination in the treatment of primary open-angle glaucomahttps://orcid.org/0000-0001-6922-0464ПетровС. Ю.PetrovS. Yu.

Петров Сергей Юрьевич — д-р мед. наук, начальник отдела глаукомы.

ул. Садовая-Черногрязская, д. 14/19, Москва, 105062

Sergey Yu. Petrov — Dr. of Med. Sci., head of glaucoma department.

14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062

glaucomatosis@gmail.comhttps://orcid.org/0000-0002-8090-6034МаркеловаО. И.MarkelovaO. I.

Маркелова Оксана Игоревна — аспирант.

ул. Садовая-Черногрязская, д. 14/19, Москва, 105062

Oksana I. Markelova — PhD student.

14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062

ФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава РоссииРоссияHelmholtz National Medical Research Center of Eye DiseasesRussian Federation202525032025181157162Copyright © Петров С.Ю., Маркелова О.И., 20252025Петров С.Ю., Маркелова О.И.Petrov S.Y., Markelova O.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://roj.igb.ru/jour/article/view/1705

Фиксированная комбинация латанопроста и тимолола (ФКЛТ) обеспечивает клинически значимое снижение внутриглазного давления (ВГД) с благоприятным профилем переносимости у пациентов с глаукомой и офтальмогипертензией, недостаточно контролируемых на монотерапии. ФКЛТ способствует лучшему контролю ВГД по сравнению с ее отдельными компонентами, демонстрируя при этом благоприятный профиль безопасности и переносимости. ФКЛТ в режиме однократной вечерней инстилляции обеспечивает лучшее качество 24-часового контроля ВГД. Применение ФКЛТ сопровождается меньшим количеством побочных эффектов, более удобным дозированием и меньшим воздействием консервантов. Эти преимущества положительно влияют на качество жизни, приверженность терапии и, возможно, на будущий результат хирургического лечения глаукомы.

Latanoprost/timolol fixed combination (FCLT) provides clinically significant IOP reduction with a favorable tolerability profile in patients with glaucoma and ocular hypertension inadequately controlled on monotherapy. FCLT provides better IOP control compared to its components, while demonstrating a favorable safety and tolerability profile. FCLT as a single dose evening instillation provides better 24-hour IOP control. FCLT is associated with fewer side effects, more convenient dosing, and lower exposure to preservatives. These advantages have a positive impact on quality of life, compliance, and possibly on the future outcome of glaucoma surgery.

глаукомафиксированная комбинациялатанопросттимололгипотензивная терапияglaucomafixed combinationlatanoprosttimololhypotensive treatmentОбзор подготовлен при поддержке компании «Виатрис».The review was prepared with the support of Viatris.ReferencesAngeli A, Supuran CT. Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013—2018). Expert Opin Ther Pat. 2019; 29 (10): 793—803. doi: 10.1080/13543776.2019.1661992Angeli A, Supuran CT. Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013—2018). Expert Opin Ther Pat. 2019; 29 (10): 793—803. doi: 10.1080/13543776.2019.1661992Korbecki J, Baranowska-Bosiacka I, Gutowska I, Chlubek D. Cyclooxygenase pathways. Acta Biochim Pol. 2014; 61 (4): 639—49. PMID: 25343148.Korbecki J, Baranowska-Bosiacka I, Gutowska I, Chlubek D. Cyclooxygenase pathways. Acta Biochim Pol. 2014; 61 (4): 639—49. PMID: 25343148.Нестеров А.П. Глаукома. Москва: Медицина; 1995. [Nesterov A.P. Glaucoma. Moscow: Medicine; 1995 (In Russ.)].Нестеров А.П. Глаукома. Москва: Медицина; 1995. [Nesterov A.P. Glaucoma. Moscow: Medicine; 1995 (In Russ.)].Park JH, Yoo C, Chung HW, Kim YY. Effect of prostaglandin analogues on anterior scleral thickness and corneal thickness in patients with primary openangle glaucoma. Sci Rep. 2021; 11 (1): 11098. doi: 10.1038/s41598-021-90696-4Park JH, Yoo C, Chung HW, Kim YY. Effect of prostaglandin analogues on anterior scleral thickness and corneal thickness in patients with primary openangle glaucoma. Sci Rep. 2021; 11 (1): 11098. doi: 10.1038/s41598-021-90696-4Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121 (11): 208-190. doi: 10.1016/j.ophtha.2014.05.013Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121 (11): 208-190. doi: 10.1016/j.ophtha.2014.05.013Sharif NA, Davis TL, Williams GW. [3H]AL-5848 ([3H]9beta-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J Pharm Pharmacol. 1999; 51 (6): 685-94. doi: 10.1211/0022357991772989Sharif NA, Davis TL, Williams GW. [3H]AL-5848 ([3H]9beta-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J Pharm Pharmacol. 1999; 51 (6): 685-94. doi: 10.1211/0022357991772989Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: A Systematic review and network meta-analysis. Ophthalmology. 2016; 123 (1): 129-40. doi: 10.1016/j.ophtha.2015.09.005Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: A Systematic review and network meta-analysis. Ophthalmology. 2016; 123 (1): 129-40. doi: 10.1016/j.ophtha.2015.09.005Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999; 106 (4): 653-62. doi: 10.1016/s0161-6420(99)90147-1Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999; 106 (4): 653-62. doi: 10.1016/s0161-6420(99)90147-1Prum BE, Jr, Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma preferred practice pattern guidelines. Ophthalmology. 2016; 123 (1): P41-P111. doi: 10.1016/j.ophtha.2015.10.053Prum BE, Jr, Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma preferred practice pattern guidelines. Ophthalmology. 2016; 123 (1): P41-P111. doi: 10.1016/j.ophtha.2015.10.053Babic N. Fixed combinations of glaucoma medications. Srp Arh Celok Lek. 2015; 143 (9-10): 626-31. doi: 10.2298/sarh1510626bBabic N. Fixed combinations of glaucoma medications. Srp Arh Celok Lek. 2015; 143 (9-10): 626-31. doi: 10.2298/sarh1510626bMachen L, Razeghinejad R, Myers JS. Fixed-combination topical antihypertensive ophthalmic agents. Expert Opin Pharmacother. 2020; 21 (10): 1269-82. doi: 10.1080/14656566.2020.1743264Machen L, Razeghinejad R, Myers JS. Fixed-combination topical antihypertensive ophthalmic agents. Expert Opin Pharmacother. 2020; 21 (10): 1269-82. doi: 10.1080/14656566.2020.1743264Wang T, Cao L, Jiang Q, Zhang T. Topical medication therapy for glaucoma and ocular hypertension. Front Pharmacol. 2021; 12: 749858. doi: 10.3389/fphar.2021.749858Wang T, Cao L, Jiang Q, Zhang T. Topical medication therapy for glaucoma and ocular hypertension. Front Pharmacol. 2021; 12: 749858. doi: 10.3389/fphar.2021.749858Konstas AG, Schmetterer L, Costa VP, et al. Current and emerging fixed combination therapies in glaucoma: a safety and tolerability review. Expert Opin Drug Saf. 2020; 19 (11): 1445-60. doi: 10.1080/14740338.2020.1826928Konstas AG, Schmetterer L, Costa VP, et al. Current and emerging fixed combination therapies in glaucoma: a safety and tolerability review. Expert Opin Drug Saf. 2020; 19 (11): 1445-60. doi: 10.1080/14740338.2020.1826928Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol. 2005; 5 (5): 459-63. doi: 10.1097/01.all.0000183112.86181.9eBaudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol. 2005; 5 (5): 459-63. doi: 10.1097/01.all.0000183112.86181.9eHollo G, Katsanos A, Boboridis KG, Irkec M, Konstas AGP. Preservative-free Prostaglandin Analogs and Prostaglandin/Timolol fixed combinations in the treatment of glaucoma: Efficacy, safety and potential advantages. Drugs. 2018; 78 (1): 39-64. doi: 10.1007/s40265-017-0843-9Hollo G, Katsanos A, Boboridis KG, Irkec M, Konstas AGP. Preservative-free Prostaglandin Analogs and Prostaglandin/Timolol fixed combinations in the treatment of glaucoma: Efficacy, safety and potential advantages. Drugs. 2018; 78 (1): 39-64. doi: 10.1007/s40265-017-0843-9Zimmerman T.J. Timolol maleate — a new glaucoma medication? Invest Ophthalmol Vis Sci. 1977 Aug; 16 (8): 687-8. PMID: 407171.Zimmerman T.J. Timolol maleate — a new glaucoma medication? Invest Ophthalmol Vis Sci. 1977 Aug; 16 (8): 687-8. PMID: 407171.Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmol. 2018; 96 (3): e277-e84. doi: 10.1111/aos.13568Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmol. 2018; 96 (3): e277-e84. doi: 10.1111/aos.13568Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014; 311 (18): 1901-11. doi: 10.1001/jama.2014.3192Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014; 311 (18): 1901-11. doi: 10.1001/jama.2014.3192Алексеев И.Б., Волкова А.В., Алексеева Л.И. Ксалаком: возможности и преимущества препарата в терапии глаукомы. Вестник офтальмологии. 2022; 138 (5): 119-25. doi: 10.17116/oftalma2022138051119Alekseev I.B., Volkova A.V., Alekseeva L.I. Xalacom: possibilities and advantages of the drug in the treatment of patients with glaucoma. Vestnik oftal'mologii. 2022; 138 (5): 119-25 (In Russ.). doi: 10.17116/oftalma2022138051119Золотарев А.В., Карлова Е.В. О механизме действия фиксированной комбинации латанопроста и тимолола. Офтальмологические ведомости. 2011; 4 (2): 71-5.Zolotaryov A.V., Karlova E.V. About the mechanism of action of the fixed combination of latanoprost and timolol. Ophthalmology reports. 2011; 4 (2): 71—5 (In Russ.).Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging. 2007; 24 (12): 1007—16. doi: 10.2165/00002512-200724120-00004Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging. 2007; 24 (12): 1007—16. doi: 10.2165/00002512-200724120-00004Feldman RM. An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother. 2004; 5 (4): 909-21. doi: 10.1517/14656566.5.4.909Feldman RM. An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother. 2004; 5 (4): 909-21. doi: 10.1517/14656566.5.4.909Higginbotham EJ, Feldman R, Stiles M, Dubiner H, Fixed Combination Investigative G. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002; 120 (7): 915-22. doi: 10.1001/archopht.120.7.915Higginbotham EJ, Feldman R, Stiles M, Dubiner H, Fixed Combination Investigative G. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002; 120 (7): 915-22. doi: 10.1001/archopht.120.7.915Inoue K, Fujimoto T, Higa R, et al. Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5 % fixed combination eyedrops from latanoprost 0.005% monotherapy. Clin Ophthalmol. 2012; 6: 771-5. doi: 10.2147/OPTH.S31085Inoue K, Fujimoto T, Higa R, et al. Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5 % fixed combination eyedrops from latanoprost 0.005% monotherapy. Clin Ophthalmol. 2012; 6: 771-5. doi: 10.2147/OPTH.S31085Konstas AG, Pikilidou MI, Tsironi S, et al. 24-hour intraocular pressure and blood pressure levels with latanoprost/timolol fixed combination versus timolol. Curr Eye Res. 2009; 34 (5): 369-77. doi: 10.1080/02713680902850075Konstas AG, Pikilidou MI, Tsironi S, et al. 24-hour intraocular pressure and blood pressure levels with latanoprost/timolol fixed combination versus timolol. Curr Eye Res. 2009; 34 (5): 369-77. doi: 10.1080/02713680902850075Stewart WC, Stewart JA, Day D, Sharpe E.D. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol Scand. 2003; 81 (3): 242-6. doi: 10.1034/j.1600-0420.2003.00065.xStewart WC, Stewart JA, Day D, Sharpe E.D. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol Scand. 2003; 81 (3): 242-6. doi: 10.1034/j.1600-0420.2003.00065.xTabet R, Stewart WC, Feldman R, Konstas AG. A review of additivity to prostaglandin analogs: fixed and unfixed combinations. Surv Ophthalmol. 2008; 53 Suppl1(S85-92). doi: 10.1016/j.survophthal.2008.08.011Tabet R, Stewart WC, Feldman R, Konstas AG. A review of additivity to prostaglandin analogs: fixed and unfixed combinations. Surv Ophthalmol. 2008; 53 Suppl1(S85-92). doi: 10.1016/j.survophthal.2008.08.011Cheng JW, Cai JP, Li Y, Wei RL. A meta-analysis of topical prostaglandin analogs in the treatment of chronic angle-closure glaucoma. J Glaucoma. 2009; 18 (9): 652-7. doi: 10.1097/IJG.0b013e31819c49d4Cheng JW, Cai JP, Li Y, Wei RL. A meta-analysis of topical prostaglandin analogs in the treatment of chronic angle-closure glaucoma. J Glaucoma. 2009; 18 (9): 652-7. doi: 10.1097/IJG.0b013e31819c49d4Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. 2009; 116 (7): 1243-9. doi: 10.1016/j.ophtha.2009.01.036Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. 2009; 116 (7): 1243-9. doi: 10.1016/j.ophtha.2009.01.036Cheng JW, Cheng SW, Gao LD, Lu GC, Wei RL. Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One. 2012; 7 (9): e45079. doi: 10.1371/journal.pone.0045079Cheng JW, Cheng SW, Gao LD, Lu GC, Wei RL. Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One. 2012; 7 (9): e45079. doi: 10.1371/journal.pone.0045079Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013; 29 (4): 382-9. doi: 10.1089/jop.2012.0186Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013; 29 (4): 382-9. doi: 10.1089/jop.2012.0186Webers CA, Beckers HJ, Zeegers MP, et al. The intraocular pressure-lowering effect of prostaglandin analogs combined with topical beta-blocker therapy: a systematic review and meta-analysis. Ophthalmology. 2010; 117 (11): 2067-74 e1-6. doi: 10.1016/j.ophtha.2010.03.024Webers CA, Beckers HJ, Zeegers MP, et al. The intraocular pressure-lowering effect of prostaglandin analogs combined with topical beta-blocker therapy: a systematic review and meta-analysis. Ophthalmology. 2010; 117 (11): 2067-74 e1-6. doi: 10.1016/j.ophtha.2010.03.024Larsson LI. Effect on intraocular pressure during 24 hours after repeated administration of the fixed combination of latanoprost 0.005 % and timolol 0.5 % in patients with ocular hypertension. J Glaucoma. 2001; 10 (2): 109-14. doi: 10.1097/00061198-200104000-00007Larsson LI. Effect on intraocular pressure during 24 hours after repeated administration of the fixed combination of latanoprost 0.005 % and timolol 0.5 % in patients with ocular hypertension. J Glaucoma. 2001; 10 (2): 109-14. doi: 10.1097/00061198-200104000-00007Centofanti M, Oddone F, Vetrugno M, et al. Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur J Ophthalmol. 2009; 19 (1): 66-71. doi: 10.1177/112067210901900110Centofanti M, Oddone F, Vetrugno M, et al. Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur J Ophthalmol. 2009; 19 (1): 66-71. doi: 10.1177/112067210901900110Diestelhorst M, Almegard B. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 1998; 236 (8): 577-81. doi: 10.1007/s004170050124Diestelhorst M, Almegard B. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 1998; 236 (8): 577-81. doi: 10.1007/s004170050124Higginbotham EJ, Olander KW, Kim EE, et al. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol. 2010; 128 (2): 165-72. doi: 10.1001/archophthalmol.2009.384Higginbotham EJ, Olander KW, Kim EE, et al. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol. 2010; 128 (2): 165-72. doi: 10.1001/archophthalmol.2009.384Konstas AG, Boboridis K, Tzetzi D, et al. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol. 2005; 123 (7): 898-902. doi: 10.1001/archopht.123.7.898Konstas AG, Boboridis K, Tzetzi D, et al. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol. 2005; 123 (7): 898-902. doi: 10.1001/archopht.123.7.898Konstas AG, Lake S, Economou AI, et al. 24-Hour control with a latanoprost-timolol fixed combination vs timolol alone. Arch Ophthalmol. 2006; 124 (11): 1553-7. doi: 10.1001/archopht.124.11.1553Konstas AG, Lake S, Economou AI, et al. 24-Hour control with a latanoprost-timolol fixed combination vs timolol alone. Arch Ophthalmol. 2006; 124 (11): 1553-7. doi: 10.1001/archopht.124.11.1553Lazaridou MN, Montgomery DM, Ho WO, Jaberoo D. Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/ timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database. Curr Med Res Opin. 2008; 24 (10): 2725-8. doi: 10.1185/03007990802312567Lazaridou MN, Montgomery DM, Ho WO, Jaberoo D. Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/ timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database. Curr Med Res Opin. 2008; 24 (10): 2725-8. doi: 10.1185/03007990802312567Pfeiffer N, European Latanoprost Fixed Combination Study G. A comparison ofthe fixed combination oflatanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002; 240 (11): 893-9. doi: 10.1007/s00417-002-0553-0Pfeiffer N, European Latanoprost Fixed Combination Study G. A comparison ofthe fixed combination oflatanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002; 240 (11): 893-9. doi: 10.1007/s00417-002-0553-0Астахов Ю.С., Гозиев С.Д., Шихалиев Д.Р. Влияние нефиксированной и фиксированной комбинации 0,5 % тимолола и 0,005 % латанопроста на местную и системную гемодинамику при лечении пациентов с ПОУГ. Офтальмологические ведомости. 2009; 2 (1): 12-7.Astakhov Yu. S., Goziev S. J., Shikhaliev D. J. The influence of unfixed and fixed combination of Timolol 0.5 % and Latanoprost 0.005 % on local and systemic hemodynamics in treatment of patients with POAG. Ophthalmology reports. 2009; 2 (1): 12-7 (In Russ.).Астахов Ю.С., Логинов Г.Н., Акопов Е.Л., Гозиев С.Д. Оценка безопасности и эффективности применения препарата Ксалаком при лечении больных с первичной открытоугольной глаукомой. Вестник Авиценны. 2008; 1 (34): 63-8.Astakhov Yu.S., Loginov G.N., Akopov E.L., Goziev S.D. The value of safity and effectivity of the preparate Ksalakom under treatment of patients with first openangle glaucoma. Avicenna bulletin. 2008; 1 (34): 63-8 (In Russ.).Palmberg P, Kim EE, Kwok KK, Tressler CS, Canada, United States Fixed Combination Latanoprost/Timolol Study G. A 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy. Eur J Ophthalmol. 2010; 20 (4): 708-18. doi: 10.1177/112067211002000411Palmberg P, Kim EE, Kwok KK, Tressler CS, Canada, United States Fixed Combination Latanoprost/Timolol Study G. A 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy. Eur J Ophthalmol. 2010; 20 (4): 708-18. doi: 10.1177/112067211002000411Hamacher T, Schinzel M, Scholzel-Klatt A, et al. Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005 % / timolol maleate 0.5 % fixed combination from monotherapies and adjunctive therapies. Br J Ophthalmol. 2004; 88 (10): 1295-8. doi: 10.1136/bjo.2004.043232Hamacher T, Schinzel M, Scholzel-Klatt A, et al. Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005 % / timolol maleate 0.5 % fixed combination from monotherapies and adjunctive therapies. Br J Ophthalmol. 2004; 88 (10): 1295-8. doi: 10.1136/bjo.2004.043232Shin DH, Feldman RM, Sheu WP, Fixed Combination Latanoprost/Timolol Study G. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology. 2004; 111 (2): 276-82. doi: 10.1016/j.ophtha.2003.05.019Shin DH, Feldman RM, Sheu WP, Fixed Combination Latanoprost/Timolol Study G. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology. 2004; 111 (2): 276-82. doi: 10.1016/j.ophtha.2003.05.019Magacho L, Reis R, Shetty RK, Santos LC, Avila MP. Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication. Ophthalmology. 2006 Mar; 113 (3): 442-5. doi: 10.1016/j.ophtha.2005.11.011Magacho L, Reis R, Shetty RK, Santos LC, Avila MP. Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication. Ophthalmology. 2006 Mar; 113 (3): 442-5. doi: 10.1016/j.ophtha.2005.11.011Schwenn O, Heckmann B, Guzy C, Miller PJ. Long-term effect of latanoprost/ timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study. BMC Ophthalmol. 2010; 10: 21. doi: 10.1186/1471-2415-10-21Schwenn O, Heckmann B, Guzy C, Miller PJ. Long-term effect of latanoprost/ timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study. BMC Ophthalmol. 2010; 10: 21. doi: 10.1186/1471-2415-10-21Апостолова А.С. Сравнительное исследование эффективности препаратов Ксалатан и Ксалаком (Pfizer, США) в лечении псевдоэксфолиативной глаукомы. Офтальмологические ведомости. 2013; 6 (3): 71-4.Apostolova A.S. A comparative study of Xalatan and Xalacom (Pfizer, USA) efficacy in the treatment of pseudoexfoliative glaucoma. Ophthalmology reports. 2013; 6 (3): 71-4 (In Russ.).Konstas AG, Hollo G, Mikropoulos D, et al. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J Ophthalmol. 2010; 94 (2): 209-13. doi: 10.1136/bjo.2008.155317Konstas AG, Hollo G, Mikropoulos D, et al. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J Ophthalmol. 2010; 94 (2): 209-13. doi: 10.1136/bjo.2008.155317Konstas AG, Mikropoulos D, Haidich AB, Ntampos KS, Stewart WC. Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Br J Ophthalmol. 2009; 93 (4): 481-5. doi: 10.1136/bjo.2008.147322Konstas AG, Mikropoulos D, Haidich AB, Ntampos KS, Stewart WC. Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Br J Ophthalmol. 2009; 93 (4): 481-5. doi: 10.1136/bjo.2008.147322Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995; 102 (12): 1743-52. doi: 10.1016/s0161-6420(95)30798-1Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995; 102 (12): 1743-52. doi: 10.1016/s0161-6420(95)30798-1Konstas AG, Nakos E, Tersis I, et al. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol. 2002; 133 (6): 753-7. doi: 10.1016/s0002-9394(02)01460-5Konstas AG, Nakos E, Tersis I, et al. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol. 2002; 133 (6): 753-7. doi: 10.1016/s0002-9394(02)01460-5Takmaz T, Asik S, Kurkcuoglu P, Gurdal C, Can I. Comparison of intraocular pressure lowering effect of once daily morning vs evening dosing of latanoprost/ timolol maleate combination. Eur J Ophthalmol. 2008; 18 (1): 60-5. doi: 10.1177/112067210801800110Takmaz T, Asik S, Kurkcuoglu P, Gurdal C, Can I. Comparison of intraocular pressure lowering effect of once daily morning vs evening dosing of latanoprost/ timolol maleate combination. Eur J Ophthalmol. 2008; 18 (1): 60-5. doi: 10.1177/112067210801800110Varma R, Hwang LJ, Grunden JW, Bean GW. Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/ timolol versus latanoprost or timolol monotherapy. Br J Ophthalmol. 2010; 94 (1): 80-4. doi: 10.1136/bjo.2009.162107Varma R, Hwang LJ, Grunden JW, Bean GW. Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/ timolol versus latanoprost or timolol monotherapy. Br J Ophthalmol. 2010; 94 (1): 80-4. doi: 10.1136/bjo.2009.162107Konstas AG, Quaranta L, Mikropoulos DG, et al. Peak intraocular pressure and glaucomatous progression in primary open-angle glaucoma. J Ocul Pharmacol Ther. 2012; 28 (1): 26-32. doi: 10.1089/jop.2011.0081Konstas AG, Quaranta L, Mikropoulos DG, et al. Peak intraocular pressure and glaucomatous progression in primary open-angle glaucoma. J Ocul Pharmacol Ther. 2012; 28 (1): 26-32. doi: 10.1089/jop.2011.0081Martinez A, Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/ timolol fixed combination in open-angle glaucoma patients. Eye (Lond). 2009; 23 (4): 810-8. doi: 10.1038/eye.2008.148Martinez A, Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/ timolol fixed combination in open-angle glaucoma patients. Eye (Lond). 2009; 23 (4): 810-8. doi: 10.1038/eye.2008.148Martinez A, Sanchez M. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin. 2007; 23 (5): 1025-32. doi: 10.1185/030079907x182149Martinez A, Sanchez M. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin. 2007; 23 (5): 1025-32. doi: 10.1185/030079907x182149Topouzis F, Melamed S, Danesh-Meyer H, et al. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004 % / timolol 0.5 % to once-daily latanoprost 0.005 % / timolol 0.5 % in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2007; 17 (2): 183-90. doi: 10.1177/112067210701700206Topouzis F, Melamed S, Danesh-Meyer H, et al. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004 % / timolol 0.5 % to once-daily latanoprost 0.005 % / timolol 0.5 % in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2007; 17 (2): 183-90. doi: 10.1177/112067210701700206Konstas AG, Mikropoulos DG, Embeslidis T, et al. 24-h Intraocular pressure control with evening-dosed travoprost/timolol, compared with latanoprost/ timolol, fixed combinations in exfoliative glaucoma. Eye (Lond). 2010; 24 (10): 1606-13. doi: 10.1038/eye.2010.100Konstas AG, Mikropoulos DG, Embeslidis T, et al. 24-h Intraocular pressure control with evening-dosed travoprost/timolol, compared with latanoprost/ timolol, fixed combinations in exfoliative glaucoma. Eye (Lond). 2010; 24 (10): 1606-13. doi: 10.1038/eye.2010.100Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008; 53 Suppl1(S93-105). doi: 10.1016/j.survophthal.2008.08.004Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008; 53 Suppl1(S93-105). doi: 10.1016/j.survophthal.2008.08.004Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol. 1998; 126 (1): 37-41. doi: 10.1016/s0002-9394(98)00071-3Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol. 1998; 126 (1): 37-41. doi: 10.1016/s0002-9394(98)00071-3Horsley MB, Chen TC. The use of prostaglandin analogs in the uveitic patient. Semin Ophthalmol. 2011; 26 (4-5): 285-9. doi: 10.3109/08820538.2011.588650Horsley MB, Chen TC. The use of prostaglandin analogs in the uveitic patient. Semin Ophthalmol. 2011; 26 (4-5): 285-9. doi: 10.3109/08820538.2011.588650Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol. 2002; 47 Suppl 1 (S219. doi: 10.1016/s0039-6257(02)00328-4Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol. 2002; 47 Suppl 1 (S219. doi: 10.1016/s0039-6257(02)00328-4Markomichelakis NN, Kostakou A, Halkiadakis I, et al. Efficacy and safety of latanoprost in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol. 2009; 247 (6): 775-80. doi: 10.1007/s00417-009-1036-3Markomichelakis NN, Kostakou A, Halkiadakis I, et al. Efficacy and safety of latanoprost in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol. 2009; 247 (6): 775-80. doi: 10.1007/s00417-009-1036-3Alm A, Grunden JW, Kwok KK. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. J Glaucoma. 2011; 20 (4): 215-22. doi: 10.1097/IJG.0b013e3181e08121Alm A, Grunden JW, Kwok KK. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. J Glaucoma. 2011; 20 (4): 215-22. doi: 10.1097/IJG.0b013e3181e08121Jayaprakasam A, Ghazi-Nouri S. Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues. Orbit. 2010; 29 (6): 357-9. doi: 10.3109/01676830.2010.527028Jayaprakasam A, Ghazi-Nouri S. Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues. Orbit. 2010; 29 (6): 357-9. doi: 10.3109/01676830.2010.527028Shah M, Lee G, Lefebvre DR, et al. A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS One. 2013; 8 (5): e61638. doi: 10.1371/journal.pone.0061638Shah M, Lee G, Lefebvre DR, et al. A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS One. 2013; 8 (5): e61638. doi: 10.1371/journal.pone.0061638Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006; 47 (7): 2917-23. doi: 10.1167/iovs.05-1253Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006; 47 (7): 2917-23. doi: 10.1167/iovs.05-1253Казанова С.Ю. Побочные эффекты аналогов простагландинов, используемых в офтальмологической практике. Российский офтальмологический журнал. 2021; 14 (2): 85-9. https://doi.org/10.21516/2072-0076-2021-14-2-85-89Kazanova S.Yu. Adverse effects of prostaglandin analogues used in ophthalmological practice. Russian ophthalmological journal. 2021; 14 (2): 85-9 (In Russ.). https://doi.org/10.21516/2072-0076-2021-14-2-85-89Taniguchi T, Kitazawa Y. The potential systemic effect of topically applied beta-blockers in glaucoma therapy. Curr Opin Ophthalmol. 1997; 8 (2): 55-8. doi: 10.1097/00055735-199704000-00010Taniguchi T, Kitazawa Y. The potential systemic effect of topically applied beta-blockers in glaucoma therapy. Curr Opin Ophthalmol. 1997; 8 (2): 55-8. doi: 10.1097/00055735-199704000-00010

The authors declare that there are no conflicts of interest present.